Navigation Links
Infosys Technologies and Elan Pharmaceuticals Apply Co-creation Model to Transform Discovery Research

FREMONT, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Infosys Technologies Limited (Nasdaq: INFY) today announced that it will design and implement the Research Informatics System (RISe) at Elan Pharmaceuticals, Inc (NYSE: ELN), a leading biotechnology company, to accelerate discovery research using a path-breaking co-creation engagement model that leverages Infosys' existing intellectual property in this field.

"We are confident that partnering and collaborating with Infosys will create a comprehensive informatics platform for our discovery research needs," said Ajay Shah, Director – Research Informatics, Elan Pharmaceuticals. "We selected Infosys after a competitive Proof-of-Concept phase during which they fully established their credentials and investments in this changing field of discovery research, and demonstrated flexibility and maturity in terms of rapid application development using Agile and Scrum methodologies. With Infosys' solution and engagement model, Elan will be able to lower costs for scientific operation and facilitate innovation."

As Elan's informatics system, RISe will leverage Infosys' Scientific Innovation Solution for knowledge collaboration. Novel ways to unlock disparate data spread across in-house research labs and other commercial or public sources will be presented to scientists in context of their research needs. This will result in, among other things, a customized registry, and inventory and a workflow management system for biological entities.

Elan and its research partners could realize significant gains in research productivity by focused and efficient selection of candidate drugs or biologics with the new RISe. Linking silos of heterogeneous data will not only contribute to a more effective selection process of biologics but could also reduce time to validate them clinically. Furthermore, the new system will reduce time spent on registering and experimenting with bio-entities, increase collaboration, and reduce chances of downstream failure.

Future versions of the software may enable integration of RISe with electronic lab notebook and analytical dashboards which will enable more efficient research knowledge management.

The co-creation engagement model enables Infosys to retain ownership of co-developed IP as part of the implementation. Relevant components of this reference implementation can be reused or repurposed by Infosys to deliver faster business benefits at other Life Sciences organizations.

"Elan's vision to create a scalable research informatics system for scientists to collaborate better, dovetails perfectly with our investments in solutions that improve scientific innovation and our efforts to streamline discovery research," said R Arun Kumar, head of Infosys' Global Life Sciences Practice, Infosys Technologies.

More information can be found at Infosys' Scientific Innovation Solution website:

About Elan

Elan Corporation, plc is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. Elan shares trade on the New York and Irish Stock Exchanges. For additional information about the company, please visit

About Infosys Technologies Ltd.

Infosys (Nasdaq: INFY) defines, designs and delivers IT-enabled business solutions that help Global 2000 companies win in a Flat World. These solutions focus on providing strategic differentiation and operational superiority to clients. With Infosys, clients are assured of a transparent business partner, world-class processes, speed of execution and the power to stretch their IT budget by leveraging the Global Delivery Model that Infosys pioneered. Infosys has over 109,000 employees in over 50 offices worldwide. Infosys is part of the NASDAQ-100 Index and The Global Dow. For more information, visit

Infosys Safe Harbor

Statements in connection with this release may include forward-looking statements within the meaning of US Securities laws intended to qualify for the "safe harbor" under the Private Securities Litigation Reform Act. These forward-looking statements are subject to risks and uncertainties including those described in our SEC filings available at Opens in new window including our Annual Report on Form 20-F for the year ended March 31, 2009, and our other recent filings, and actual results may differ materially from those projected by forward-looking statements. We may make additional written and oral forward-looking statements but do not undertake, and disclaim any obligation, to update them.

SOURCE Infosys Technologies Ltd.



SOURCE Infosys Technologies Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioSpecifics Technologies Corp. Announces FDA Approval of XIAFLEX(TM) for Treatment of Dupuytrens Contracture
2. Ron Peele Named President of STB Lifesaving Technologies(R)
3. Palomar Medical Technologies to Host Fourth Quarter and Year End 2009 Financial Results Conference Call and Webcast on February 11, 2010
4. Wound Management Technologies Completes Acquisition of Secure eHealth, LLC and Other Assets from VirtualHealth Technologies; Robert Tapales Appointed President of Secure eHealth, LLC
5. VirtualHealth Technologies Completes Sale of Secure eHealth, LLC and Other Assets to Wound Management Technologies; Robert Tapales Appointed President of Secure eHealth, LLC
6. Global Med Technologies(R) Solution of Choice for Important Regional Blood Center
7. Wound Management Technologies, Inc. Engages Miller Tabak, A National Investment Banking Firm Specializing in the Healthcare Market Space
8. Greenway Medical Technologies Advances Interoperability at Integrating the Healthcare Enterprise (IHE) North America Connectathon
9. Neurobiological Technologies Announces Filing of Certificate of Dissolution and Closing of Stock Transfer Books
10. Wound Management Technologies, Inc. Targets Multi-Billion Dollar Biomaterials Market; Releases Update on Resorbable Orthopedics
11. AVAX Technologies, Inc. Closes Bridge Financing
Post Your Comments:
(Date:11/26/2015)... PUNE, India , November 26, ... --> --> ... Research Report" and "Investigation Report on ... 2019 and 2021 forecasts data and ... library. . ...
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ... the "2016 Future Horizons and Growth Strategies ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> --> This ... the Italian therapeutic drug monitoring market, including emerging ...
(Date:11/26/2015)... , November 26, 2015 ... the addition of the  "2016 Future ... European Cell Surface Marker Testing Market: ...  report to their offering.  --> ... addition of the  "2016 Future Horizons ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... Pixel Film ... trailer titles with ProTrailer: Vintage. This newly styled ProTrailer pack comes with 30 ... with any font, giving users limitless opportunities to stylize and create designs quickly ...
(Date:11/25/2015)... ... , ... The holiday season is jam-packed with family dinners, ... attendees is of the utmost importance. Whether you are cooking at home for ... a try this holiday season. , Turkey Croquettes ,     Ingredients: , ...
(Date:11/25/2015)... ... November 26, 2015 , ... Ministers, senior ... (EU), ANDI Pan African Centres of Excellence, and public R&D institutions, civil societies ... the opening of the 5th African Network for Drugs and Diagnostics Innovation, ANDI, ...
(Date:11/25/2015)... ... 2015 , ... Dental professionals who would like to become more proficient on ... Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE course. Courses will be held on ... co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli and Dr. D’Orazio are proud to ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of ... patients are aware of the benefits of Botox® in the treatment of moderate facial ... discomfort, soreness, and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, ...
Breaking Medicine News(10 mins):